Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Gemini Pharmaceuticals, Inc.
EIR
•Gemini Pharmaceuticals, Inc.•February 16, 2018

Gemini Pharmaceuticals, Inc. – FDA EIR, Feb 16, 2018

Record Details

Gemini Pharmaceuticals, Inc. underwent an FDA inspection from February 13-16, 2018, as an Over-The-Counter (OTC) drug and dietary supplements manufacturer in Commack, NY. The inspection, conducted pursuant to Drug Good Manufacturing Practices (GMP) and CPGM 7356.002, evaluated the firm's Quality, Facilities and Equipment, and Production & Materials systems. An FDA Form 483 was issued, detailing several significant observations.

Main violations included inadequate facility maintenance, specifically in blending rooms which were found in a poor state of repair with material buildup and deteriorating wall surfaces, posing potential contamination risks. Similarly, a pharmacy dispensing room lacked adequate environmental controls due to structural deficiencies and disrepair. The company also failed to adhere to its written procedures for sampling and examining packaging materials, as evidenced by open sampling room doors and incomplete inspection of collected samples. Furthermore, procedures for the storage and annual visual examination of reserve samples were not consistently followed, with records indicating samples were not properly inspected or pulled according to established guidelines, referencing regulatory requirements such as 21 CFR 211. Management acknowledged all observations, agreeing to take corrective actions and provide a written response within 15 business days. The firm initiated some voluntary corrections during the inspection, including drafting updated Standard Operating Procedures for facility cleaning, revising sampling protocols, and improving documentation for equipment usage, demonstrating a commitment to addressing the identified deficiencies.

Company
Gemini Pharmaceuticals, Inc.
Inspection date
February 16, 2018
Product type
drugs
Office
New York District Office
People
  • Christopher S. Fields (investigator)
  • Jose Hernandez-Guzman
  • Clyde Granger (company_representative)
  • Leonard F. Aska (company_representative)
  • Michael Finamore (recipient)
View Company Profile

ID · 1b754bc1-a15c-414b-aeeb-a97dddcbb36c

Violation Codes4
21 CFR 211.5821 CFR 211.122(a)21 CFR 211.42(c)21 CFR 211.80(a)

Full citation text and observation details available on the Dashboard.

Other documents for Gemini Pharmaceuticals, Inc.
  • 483 - 2022-07-26July 26, 2022
  • 483 - 2018-02-16February 16, 2018
  • EIR - 2015-06-30June 30, 2015
  • 483 - 2015-06-30June 30, 2015
  • 483 - 2011-06-01June 1, 2011

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Gemini Pharmaceuticals, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.